AI-generated imageGuides · Food and nutrition · Updated 2026-11-20
Will I regain weight after stopping a GLP-1 medicine?
Most people regain a good part of it. In a study of semaglutide, people regained about two-thirds of the weight they had lost within a year of stopping. Exercise helps: in one trial, people who followed an exercise program while on a GLP-1 medicine kept more weight off a year after stopping than people who only took the medicine. Stopping is a decision to make with your prescriber.
- Talk to your prescriber first. Don't stop or skip doses on your own. Ask what the plan is for after, before you stop.
- Build the exercise habit while you are on it. Lift three times a week and walk most days. The habit has to be in place before the medicine goes.
- Keep protein and regular meals. Eat at regular times, with breakfast and enough protein.
- Keep weighing and logging. Check your weight and your food so you notice a slow climb early.
What the trials show
| Study | On the medicine | After stopping |
|---|---|---|
| Semaglutide, 327 people followed for a year after stopping | Lost 17.3 percent of body weight in 68 weeks | Regained 11.6 percentage points in a year. Still 5.6 percent below the start. |
| Tirzepatide, switched to placebo after 36 weeks | Lost 20.9 percent in 36 weeks | Regained 14.0 percent over the next 52 weeks |
| Tirzepatide, same trial, stayed on it | Lost 20.9 percent in 36 weeks | Lost another 5.5 percent over the next 52 weeks |
The pattern is clear. Appetite returns when the medicine stops, and weight follows for most people. These are averages, so some people regained more and some less.
This is not a failure of willpower. The medicine was turning hunger down, and without it hunger comes back.
Semaglutide is sold under brand names such as Ozempic and Wegovy. Tirzepatide is sold as Mounjaro and Zepbound. Liraglutide is sold as Saxenda and Victoza. This page uses the generic names, as the studies do. Brand names differ by country.
What helped people keep weight off
One trial tested this head on. In Denmark, 195 adults first lost about 13 kg on a low-calorie diet. Then they spent a year in one of four groups: a supervised exercise program, the GLP-1 medicine liraglutide, both, or neither.
After that year, all treatment stopped. A year later the researchers checked again:
- People who had only taken the medicine regained 6.0 kg more than people who had only done the exercise program.
- The group that had done both weighed 5.1 kg less than the medicine-only group.
People who had done the exercise program held their weight and body composition through that year.
The exercise program in that trial was supervised, at moderate to vigorous effort. The lesson is not that a few walks replace the medicine. It is that habits built while you are on it are still yours when it stops.
Habits linked to keeping weight off
A 2025 advisory from four medical societies in nutrition and obesity care lists habits seen in people who keep weight off for years:
- Eating at regular times each day
- Eating breakfast
- Choosing mostly whole foods with fiber and protein
- Keeping sugary drinks and snack foods low
- Staying flexible, with small treats in place of strict rules
- Keeping track of weight and food
- Being active on a regular basis
None of these need the medicine. All of them are easier to start while it is quieting your hunger.
Losing muscle makes regain worse
When weight comes off, some muscle goes with it unless you train. The 2025 advisory warns that going on and off these medicines, with weight regain in between, may add to the loss of muscle and bone when there is no structured eating and exercise plan.
That is one more reason to lift while you are on the medicine and to keep lifting after. See how to keep muscle on a GLP-1 medicine and the GLP-1 workout plan.
If you and your prescriber decide to stop
- Ask how to stop. Your prescriber decides if and how to come off. Don’t skip or stretch doses on your own.
- Have your routine in place first. Three strength days and regular walks, already a habit.
- Expect hunger to return. Plan meals ahead so you are not deciding while hungry. See how to meal prep.
- Keep protein up. See how much protein to eat.
- Weigh in regularly. A weekly average makes a slow climb easy to spot.
- Go back early. If weight is climbing, tell your prescriber sooner, not later.
If the scale stalls while you are still on the medicine, that is a different question. See why weight loss stops, and ask your prescriber before changing anything about your dose.
If tracking your weight or food starts to feel stressful or controlling, stop and talk to a professional. This page is general information, not medical advice.
Ozempic, Wegovy, Saxenda and Victoza are trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are trademarks of Eli Lilly and Company. They are named only to say which medicines this page is about. Neither company is connected to this site or endorses it.
Also asked
How fast does the weight come back?
It varies. In the semaglutide study, people regained 11.6 percentage points of body weight in the year after stopping, after losing 17.3 percent. In a tirzepatide trial, people switched to placebo regained 14.0 percent over the next 52 weeks.
Does everyone regain?
No. Those numbers are averages. A year after stopping semaglutide, people were still 5.6 percent below their starting weight on average.
Do I have to stay on a GLP-1 medicine for life?
That is a question for your prescriber. The researchers behind the semaglutide study concluded that ongoing treatment is needed to keep the results. Side effects and cost play a part too.
Does exercise really make a difference after stopping?
In one trial it did. A year after treatment ended, the group that had done supervised exercise along with the medicine weighed 5.1 kg less than the group that had only taken the medicine.
Will I regain weight after stopping Ozempic, Wegovy, Mounjaro or Zepbound?
Ozempic and Wegovy are brand names for semaglutide, and Mounjaro and Zepbound are brand names for tirzepatide. In trials of both medicines, people regained much of the lost weight on average in the year after stopping. Stopping is a decision to make with your prescriber.
Sources
- Wilding et al. (2022), Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
- Aronne et al. (2024), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
- Jensen et al. (2024), Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial
- Lundgren et al. (2021), Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
- Mozaffarian et al. (2025), Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society